

Global Orphan Indication Treatment Market Growth 2023-2029

<https://marketpublishers.com/r/GB242D15DBD7EN.html>

Date: February 2023

Pages: 104

Price: US\$ 3,660.00 (Single User License)

ID: GB242D15DBD7EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

An orphan drug is a drug used to treat a disease that cannot be produced profitably without government assistance because of the small number of patients. The classification of certain diseases, and the medicines that treat them, as 'orphan' is a matter of public policy in many countries. Given the nature of the enormous economic resources required for medical research, these medicines would have no chance of producing breakthroughs that otherwise might not have been possible without government assistance. In the United States and the European Union, orphan drugs are easier to obtain marketing authorization. There may also be additional financial incentives, such as an extension of the market exclusivity period, which would allow the pharmaceutical company to have a longer exclusivity to sell the drug. All of these measures are designed to encourage drug development, and without this kind of profit motive, few pharmaceutical companies will be willing to allocate their budgets and personnel to this type of research.

LPI (LP Information)' newest research report, the "Orphan Indication Treatment Industry Forecast" looks at past sales and reviews total world Orphan Indication Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Orphan Indication Treatment sales for 2023 through 2029. With Orphan Indication Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Orphan Indication Treatment industry.

This Insight Report provides a comprehensive analysis of the global Orphan Indication Treatment landscape and highlights key trends related to product segmentation,

company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orphan Indication Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Orphan Indication Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orphan Indication Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orphan Indication Treatment.

The global Orphan Indication Treatment market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Orphan Indication Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Orphan Indication Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Orphan Indication Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Orphan Indication Treatment players cover Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, Pfizer, Amgen, Sanofi, AstraZeneca and Takeda, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Orphan Indication Treatment market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Biologics

Non-Biologics

Segmentation by application

Hospital Pharmacy

Retail Pharmacy

Online Sales

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Bristol-Myers Squibb

Roche

Novartis

Johnson & Johnson

Pfizer

Amgen

Sanofi

AstraZeneca

Takeda

Vertex Pharmaceuticals

AbbVie

Biogen

Eli Lilly

Key Questions Addressed in this Report

What is the 10-year outlook for the global Orphan Indication Treatment market?

What factors are driving Orphan Indication Treatment market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Orphan Indication Treatment market opportunities vary by end market size?

How does Orphan Indication Treatment break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Orphan Indication Treatment Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Orphan Indication Treatment by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Orphan Indication Treatment by Country/Region, 2018, 2022 & 2029
- 2.2 Orphan Indication Treatment Segment by Type
 - 2.2.1 Biologics
 - 2.2.2 Non-Biologics
- 2.3 Orphan Indication Treatment Sales by Type
 - 2.3.1 Global Orphan Indication Treatment Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Orphan Indication Treatment Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Orphan Indication Treatment Sale Price by Type (2018-2023)
- 2.4 Orphan Indication Treatment Segment by Application
 - 2.4.1 Hospital Pharmacy
 - 2.4.2 Retail Pharmacy
 - 2.4.3 Online Sales
- 2.5 Orphan Indication Treatment Sales by Application
 - 2.5.1 Global Orphan Indication Treatment Sale Market Share by Application (2018-2023)
 - 2.5.2 Global Orphan Indication Treatment Revenue and Market Share by Application (2018-2023)
 - 2.5.3 Global Orphan Indication Treatment Sale Price by Application (2018-2023)

3 GLOBAL ORPHAN INDICATION TREATMENT BY COMPANY

3.1 Global Orphan Indication Treatment Breakdown Data by Company

3.1.1 Global Orphan Indication Treatment Annual Sales by Company (2018-2023)

3.1.2 Global Orphan Indication Treatment Sales Market Share by Company
(2018-2023)

3.2 Global Orphan Indication Treatment Annual Revenue by Company (2018-2023)

3.2.1 Global Orphan Indication Treatment Revenue by Company (2018-2023)

3.2.2 Global Orphan Indication Treatment Revenue Market Share by Company
(2018-2023)

3.3 Global Orphan Indication Treatment Sale Price by Company

3.4 Key Manufacturers Orphan Indication Treatment Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Orphan Indication Treatment Product Location Distribution

3.4.2 Players Orphan Indication Treatment Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR ORPHAN INDICATION TREATMENT BY GEOGRAPHIC REGION

4.1 World Historic Orphan Indication Treatment Market Size by Geographic Region (2018-2023)

4.1.1 Global Orphan Indication Treatment Annual Sales by Geographic Region
(2018-2023)

4.1.2 Global Orphan Indication Treatment Annual Revenue by Geographic Region
(2018-2023)

4.2 World Historic Orphan Indication Treatment Market Size by Country/Region (2018-2023)

4.2.1 Global Orphan Indication Treatment Annual Sales by Country/Region
(2018-2023)

4.2.2 Global Orphan Indication Treatment Annual Revenue by Country/Region
(2018-2023)

4.3 Americas Orphan Indication Treatment Sales Growth

4.4 APAC Orphan Indication Treatment Sales Growth

4.5 Europe Orphan Indication Treatment Sales Growth

4.6 Middle East & Africa Orphan Indication Treatment Sales Growth

5 AMERICAS

5.1 Americas Orphan Indication Treatment Sales by Country

5.1.1 Americas Orphan Indication Treatment Sales by Country (2018-2023)

5.1.2 Americas Orphan Indication Treatment Revenue by Country (2018-2023)

5.2 Americas Orphan Indication Treatment Sales by Type

5.3 Americas Orphan Indication Treatment Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Orphan Indication Treatment Sales by Region

6.1.1 APAC Orphan Indication Treatment Sales by Region (2018-2023)

6.1.2 APAC Orphan Indication Treatment Revenue by Region (2018-2023)

6.2 APAC Orphan Indication Treatment Sales by Type

6.3 APAC Orphan Indication Treatment Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Orphan Indication Treatment by Country

7.1.1 Europe Orphan Indication Treatment Sales by Country (2018-2023)

7.1.2 Europe Orphan Indication Treatment Revenue by Country (2018-2023)

7.2 Europe Orphan Indication Treatment Sales by Type

7.3 Europe Orphan Indication Treatment Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Orphan Indication Treatment by Country

8.1.1 Middle East & Africa Orphan Indication Treatment Sales by Country (2018-2023)

8.1.2 Middle East & Africa Orphan Indication Treatment Revenue by Country
(2018-2023)

8.2 Middle East & Africa Orphan Indication Treatment Sales by Type

8.3 Middle East & Africa Orphan Indication Treatment Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Orphan Indication Treatment

10.3 Manufacturing Process Analysis of Orphan Indication Treatment

10.4 Industry Chain Structure of Orphan Indication Treatment

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Orphan Indication Treatment Distributors

11.3 Orphan Indication Treatment Customer

12 WORLD FORECAST REVIEW FOR ORPHAN INDICATION TREATMENT BY GEOGRAPHIC REGION

- 12.1 Global Orphan Indication Treatment Market Size Forecast by Region
 - 12.1.1 Global Orphan Indication Treatment Forecast by Region (2024-2029)
 - 12.1.2 Global Orphan Indication Treatment Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Orphan Indication Treatment Forecast by Type
- 12.7 Global Orphan Indication Treatment Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Bristol-Myers Squibb
 - 13.1.1 Bristol-Myers Squibb Company Information
 - 13.1.2 Bristol-Myers Squibb Orphan Indication Treatment Product Portfolios and Specifications
 - 13.1.3 Bristol-Myers Squibb Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 Bristol-Myers Squibb Main Business Overview
 - 13.1.5 Bristol-Myers Squibb Latest Developments
- 13.2 Roche
 - 13.2.1 Roche Company Information
 - 13.2.2 Roche Orphan Indication Treatment Product Portfolios and Specifications
 - 13.2.3 Roche Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Roche Main Business Overview
 - 13.2.5 Roche Latest Developments
- 13.3 Novartis
 - 13.3.1 Novartis Company Information
 - 13.3.2 Novartis Orphan Indication Treatment Product Portfolios and Specifications
 - 13.3.3 Novartis Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.3.4 Novartis Main Business Overview
 - 13.3.5 Novartis Latest Developments
- 13.4 Johnson & Johnson

- 13.4.1 Johnson & Johnson Company Information
- 13.4.2 Johnson & Johnson Orphan Indication Treatment Product Portfolios and Specifications
- 13.4.3 Johnson & Johnson Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.4.4 Johnson & Johnson Main Business Overview
- 13.4.5 Johnson & Johnson Latest Developments
- 13.5 Pfizer
 - 13.5.1 Pfizer Company Information
 - 13.5.2 Pfizer Orphan Indication Treatment Product Portfolios and Specifications
 - 13.5.3 Pfizer Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.5.4 Pfizer Main Business Overview
 - 13.5.5 Pfizer Latest Developments
- 13.6 Amgen
 - 13.6.1 Amgen Company Information
 - 13.6.2 Amgen Orphan Indication Treatment Product Portfolios and Specifications
 - 13.6.3 Amgen Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.6.4 Amgen Main Business Overview
 - 13.6.5 Amgen Latest Developments
- 13.7 Sanofi
 - 13.7.1 Sanofi Company Information
 - 13.7.2 Sanofi Orphan Indication Treatment Product Portfolios and Specifications
 - 13.7.3 Sanofi Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.7.4 Sanofi Main Business Overview
 - 13.7.5 Sanofi Latest Developments
- 13.8 AstraZeneca
 - 13.8.1 AstraZeneca Company Information
 - 13.8.2 AstraZeneca Orphan Indication Treatment Product Portfolios and Specifications
 - 13.8.3 AstraZeneca Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.8.4 AstraZeneca Main Business Overview
 - 13.8.5 AstraZeneca Latest Developments
- 13.9 Takeda
 - 13.9.1 Takeda Company Information
 - 13.9.2 Takeda Orphan Indication Treatment Product Portfolios and Specifications
 - 13.9.3 Takeda Orphan Indication Treatment Sales, Revenue, Price and Gross Margin

(2018-2023)

13.9.4 Takeda Main Business Overview

13.9.5 Takeda Latest Developments

13.10 Vertex Pharmaceuticals

13.10.1 Vertex Pharmaceuticals Company Information

13.10.2 Vertex Pharmaceuticals Orphan Indication Treatment Product Portfolios and Specifications

13.10.3 Vertex Pharmaceuticals Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Vertex Pharmaceuticals Main Business Overview

13.10.5 Vertex Pharmaceuticals Latest Developments

13.11 AbbVie

13.11.1 AbbVie Company Information

13.11.2 AbbVie Orphan Indication Treatment Product Portfolios and Specifications

13.11.3 AbbVie Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 AbbVie Main Business Overview

13.11.5 AbbVie Latest Developments

13.12 Biogen

13.12.1 Biogen Company Information

13.12.2 Biogen Orphan Indication Treatment Product Portfolios and Specifications

13.12.3 Biogen Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.12.4 Biogen Main Business Overview

13.12.5 Biogen Latest Developments

13.13 Eli Lilly

13.13.1 Eli Lilly Company Information

13.13.2 Eli Lilly Orphan Indication Treatment Product Portfolios and Specifications

13.13.3 Eli Lilly Orphan Indication Treatment Sales, Revenue, Price and Gross Margin (2018-2023)

13.13.4 Eli Lilly Main Business Overview

13.13.5 Eli Lilly Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Orphan Indication Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Orphan Indication Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Biologics

Table 4. Major Players of Non-Biologics

Table 5. Global Orphan Indication Treatment Sales by Type (2018-2023) & (K Units)

Table 6. Global Orphan Indication Treatment Sales Market Share by Type (2018-2023)

Table 7. Global Orphan Indication Treatment Revenue by Type (2018-2023) & (\$ million)

Table 8. Global Orphan Indication Treatment Revenue Market Share by Type (2018-2023)

Table 9. Global Orphan Indication Treatment Sale Price by Type (2018-2023) & (US\$/Unit)

Table 10. Global Orphan Indication Treatment Sales by Application (2018-2023) & (K Units)

Table 11. Global Orphan Indication Treatment Sales Market Share by Application (2018-2023)

Table 12. Global Orphan Indication Treatment Revenue by Application (2018-2023)

Table 13. Global Orphan Indication Treatment Revenue Market Share by Application (2018-2023)

Table 14. Global Orphan Indication Treatment Sale Price by Application (2018-2023) & (US\$/Unit)

Table 15. Global Orphan Indication Treatment Sales by Company (2018-2023) & (K Units)

Table 16. Global Orphan Indication Treatment Sales Market Share by Company (2018-2023)

Table 17. Global Orphan Indication Treatment Revenue by Company (2018-2023) (\$ Millions)

Table 18. Global Orphan Indication Treatment Revenue Market Share by Company (2018-2023)

Table 19. Global Orphan Indication Treatment Sale Price by Company (2018-2023) & (US\$/Unit)

Table 20. Key Manufacturers Orphan Indication Treatment Producing Area Distribution and Sales Area

Table 21. Players Orphan Indication Treatment Products Offered
Table 22. Orphan Indication Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Orphan Indication Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Orphan Indication Treatment Sales Market Share Geographic Region (2018-2023)
Table 27. Global Orphan Indication Treatment Revenue by Geographic Region (2018-2023) & (\$ millions)
Table 28. Global Orphan Indication Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Orphan Indication Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Orphan Indication Treatment Sales Market Share by Country/Region (2018-2023)
Table 31. Global Orphan Indication Treatment Revenue by Country/Region (2018-2023) & (\$ millions)
Table 32. Global Orphan Indication Treatment Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Orphan Indication Treatment Sales by Country (2018-2023) & (K Units)
Table 34. Americas Orphan Indication Treatment Sales Market Share by Country (2018-2023)
Table 35. Americas Orphan Indication Treatment Revenue by Country (2018-2023) & (\$ Millions)
Table 36. Americas Orphan Indication Treatment Revenue Market Share by Country (2018-2023)
Table 37. Americas Orphan Indication Treatment Sales by Type (2018-2023) & (K Units)
Table 38. Americas Orphan Indication Treatment Sales by Application (2018-2023) & (K Units)
Table 39. APAC Orphan Indication Treatment Sales by Region (2018-2023) & (K Units)
Table 40. APAC Orphan Indication Treatment Sales Market Share by Region (2018-2023)
Table 41. APAC Orphan Indication Treatment Revenue by Region (2018-2023) & (\$ Millions)
Table 42. APAC Orphan Indication Treatment Revenue Market Share by Region

(2018-2023)

Table 43. APAC Orphan Indication Treatment Sales by Type (2018-2023) & (K Units)

Table 44. APAC Orphan Indication Treatment Sales by Application (2018-2023) & (K Units)

Table 45. Europe Orphan Indication Treatment Sales by Country (2018-2023) & (K Units)

Table 46. Europe Orphan Indication Treatment Sales Market Share by Country (2018-2023)

Table 47. Europe Orphan Indication Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 48. Europe Orphan Indication Treatment Revenue Market Share by Country (2018-2023)

Table 49. Europe Orphan Indication Treatment Sales by Type (2018-2023) & (K Units)

Table 50. Europe Orphan Indication Treatment Sales by Application (2018-2023) & (K Units)

Table 51. Middle East & Africa Orphan Indication Treatment Sales by Country (2018-2023) & (K Units)

Table 52. Middle East & Africa Orphan Indication Treatment Sales Market Share by Country (2018-2023)

Table 53. Middle East & Africa Orphan Indication Treatment Revenue by Country (2018-2023) & (\$ Millions)

Table 54. Middle East & Africa Orphan Indication Treatment Revenue Market Share by Country (2018-2023)

Table 55. Middle East & Africa Orphan Indication Treatment Sales by Type (2018-2023) & (K Units)

Table 56. Middle East & Africa Orphan Indication Treatment Sales by Application (2018-2023) & (K Units)

Table 57. Key Market Drivers & Growth Opportunities of Orphan Indication Treatment

Table 58. Key Market Challenges & Risks of Orphan Indication Treatment

Table 59. Key Industry Trends of Orphan Indication Treatment

Table 60. Orphan Indication Treatment Raw Material

Table 61. Key Suppliers of Raw Materials

Table 62. Orphan Indication Treatment Distributors List

Table 63. Orphan Indication Treatment Customer List

Table 64. Global Orphan Indication Treatment Sales Forecast by Region (2024-2029) & (K Units)

Table 65. Global Orphan Indication Treatment Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 66. Americas Orphan Indication Treatment Sales Forecast by Country

(2024-2029) & (K Units)

Table 67. Americas Orphan Indication Treatment Revenue Forecast by Country

(2024-2029) & (\$ millions)

Table 68. APAC Orphan Indication Treatment Sales Forecast by Region (2024-2029) & (K Units)

Table 69. APAC Orphan Indication Treatment Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 70. Europe Orphan Indication Treatment Sales Forecast by Country (2024-2029) & (K Units)

Table 71. Europe Orphan Indication Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 72. Middle East & Africa Orphan Indication Treatment Sales Forecast by Country (2024-2029) & (K Units)

Table 73. Middle East & Africa Orphan Indication Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 74. Global Orphan Indication Treatment Sales Forecast by Type (2024-2029) & (K Units)

Table 75. Global Orphan Indication Treatment Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 76. Global Orphan Indication Treatment Sales Forecast by Application (2024-2029) & (K Units)

Table 77. Global Orphan Indication Treatment Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 78. Bristol-Myers Squibb Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 79. Bristol-Myers Squibb Orphan Indication Treatment Product Portfolios and Specifications

Table 80. Bristol-Myers Squibb Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 81. Bristol-Myers Squibb Main Business

Table 82. Bristol-Myers Squibb Latest Developments

Table 83. Roche Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 84. Roche Orphan Indication Treatment Product Portfolios and Specifications

Table 85. Roche Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 86. Roche Main Business

Table 87. Roche Latest Developments

Table 88. Novartis Basic Information, Orphan Indication Treatment Manufacturing Base,

Sales Area and Its Competitors

Table 89. Novartis Orphan Indication Treatment Product Portfolios and Specifications

Table 90. Novartis Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 91. Novartis Main Business

Table 92. Novartis Latest Developments

Table 93. Johnson & Johnson Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 94. Johnson & Johnson Orphan Indication Treatment Product Portfolios and Specifications

Table 95. Johnson & Johnson Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 96. Johnson & Johnson Main Business

Table 97. Johnson & Johnson Latest Developments

Table 98. Pfizer Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 99. Pfizer Orphan Indication Treatment Product Portfolios and Specifications

Table 100. Pfizer Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 101. Pfizer Main Business

Table 102. Pfizer Latest Developments

Table 103. Amgen Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 104. Amgen Orphan Indication Treatment Product Portfolios and Specifications

Table 105. Amgen Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 106. Amgen Main Business

Table 107. Amgen Latest Developments

Table 108. Sanofi Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 109. Sanofi Orphan Indication Treatment Product Portfolios and Specifications

Table 110. Sanofi Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 111. Sanofi Main Business

Table 112. Sanofi Latest Developments

Table 113. AstraZeneca Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 114. AstraZeneca Orphan Indication Treatment Product Portfolios and Specifications

Table 115. AstraZeneca Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 116. AstraZeneca Main Business

Table 117. AstraZeneca Latest Developments

Table 118. Takeda Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 119. Takeda Orphan Indication Treatment Product Portfolios and Specifications

Table 120. Takeda Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 121. Takeda Main Business

Table 122. Takeda Latest Developments

Table 123. Vertex Pharmaceuticals Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 124. Vertex Pharmaceuticals Orphan Indication Treatment Product Portfolios and Specifications

Table 125. Vertex Pharmaceuticals Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 126. Vertex Pharmaceuticals Main Business

Table 127. Vertex Pharmaceuticals Latest Developments

Table 128. AbbVie Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 129. AbbVie Orphan Indication Treatment Product Portfolios and Specifications

Table 130. AbbVie Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 131. AbbVie Main Business

Table 132. AbbVie Latest Developments

Table 133. Biogen Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 134. Biogen Orphan Indication Treatment Product Portfolios and Specifications

Table 135. Biogen Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 136. Biogen Main Business

Table 137. Biogen Latest Developments

Table 138. Eli Lilly Basic Information, Orphan Indication Treatment Manufacturing Base, Sales Area and Its Competitors

Table 139. Eli Lilly Orphan Indication Treatment Product Portfolios and Specifications

Table 140. Eli Lilly Orphan Indication Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 141. Eli Lilly Main Business

Table 142. Eli Lilly Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Orphan Indication Treatment
- Figure 2. Orphan Indication Treatment Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Orphan Indication Treatment Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Orphan Indication Treatment Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Orphan Indication Treatment Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Biologics
- Figure 10. Product Picture of Non-Biologics
- Figure 11. Global Orphan Indication Treatment Sales Market Share by Type in 2022
- Figure 12. Global Orphan Indication Treatment Revenue Market Share by Type (2018-2023)
- Figure 13. Orphan Indication Treatment Consumed in Hospital Pharmacy
- Figure 14. Global Orphan Indication Treatment Market: Hospital Pharmacy (2018-2023) & (K Units)
- Figure 15. Orphan Indication Treatment Consumed in Retail Pharmacy
- Figure 16. Global Orphan Indication Treatment Market: Retail Pharmacy (2018-2023) & (K Units)
- Figure 17. Orphan Indication Treatment Consumed in Online Sales
- Figure 18. Global Orphan Indication Treatment Market: Online Sales (2018-2023) & (K Units)
- Figure 19. Global Orphan Indication Treatment Sales Market Share by Application (2022)
- Figure 20. Global Orphan Indication Treatment Revenue Market Share by Application in 2022
- Figure 21. Orphan Indication Treatment Sales Market by Company in 2022 (K Units)
- Figure 22. Global Orphan Indication Treatment Sales Market Share by Company in 2022
- Figure 23. Orphan Indication Treatment Revenue Market by Company in 2022 (\$ Million)
- Figure 24. Global Orphan Indication Treatment Revenue Market Share by Company in 2022

Figure 25. Global Orphan Indication Treatment Sales Market Share by Geographic Region (2018-2023)

Figure 26. Global Orphan Indication Treatment Revenue Market Share by Geographic Region in 2022

Figure 27. Americas Orphan Indication Treatment Sales 2018-2023 (K Units)

Figure 28. Americas Orphan Indication Treatment Revenue 2018-2023 (\$ Millions)

Figure 29. APAC Orphan Indication Treatment Sales 2018-2023 (K Units)

Figure 30. APAC Orphan Indication Treatment Revenue 2018-2023 (\$ Millions)

Figure 31. Europe Orphan Indication Treatment Sales 2018-2023 (K Units)

Figure 32. Europe Orphan Indication Treatment Revenue 2018-2023 (\$ Millions)

Figure 33. Middle East & Africa Orphan Indication Treatment Sales 2018-2023 (K Units)

Figure 34. Middle East & Africa Orphan Indication Treatment Revenue 2018-2023 (\$ Millions)

Figure 35. Americas Orphan Indication Treatment Sales Market Share by Country in 2022

Figure 36. Americas Orphan Indication Treatment Revenue Market Share by Country in 2022

Figure 37. Americas Orphan Indication Treatment Sales Market Share by Type (2018-2023)

Figure 38. Americas Orphan Indication Treatment Sales Market Share by Application (2018-2023)

Figure 39. United States Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 40. Canada Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Mexico Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Brazil Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 43. APAC Orphan Indication Treatment Sales Market Share by Region in 2022

Figure 44. APAC Orphan Indication Treatment Revenue Market Share by Regions in 2022

Figure 45. APAC Orphan Indication Treatment Sales Market Share by Type (2018-2023)

Figure 46. APAC Orphan Indication Treatment Sales Market Share by Application (2018-2023)

Figure 47. China Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 48. Japan Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 49. South Korea Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 50. Southeast Asia Orphan Indication Treatment Revenue Growth 2018-2023 (\$

Millions)

Figure 51. India Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Australia Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 53. China Taiwan Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 54. Europe Orphan Indication Treatment Sales Market Share by Country in 2022

Figure 55. Europe Orphan Indication Treatment Revenue Market Share by Country in 2022

Figure 56. Europe Orphan Indication Treatment Sales Market Share by Type (2018-2023)

Figure 57. Europe Orphan Indication Treatment Sales Market Share by Application (2018-2023)

Figure 58. Germany Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 59. France Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 60. UK Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 61. Italy Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Russia Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Middle East & Africa Orphan Indication Treatment Sales Market Share by Country in 2022

Figure 64. Middle East & Africa Orphan Indication Treatment Revenue Market Share by Country in 2022

Figure 65. Middle East & Africa Orphan Indication Treatment Sales Market Share by Type (2018-2023)

Figure 66. Middle East & Africa Orphan Indication Treatment Sales Market Share by Application (2018-2023)

Figure 67. Egypt Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 68. South Africa Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Israel Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Turkey Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 71. GCC Country Orphan Indication Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Manufacturing Cost Structure Analysis of Orphan Indication Treatment in 2022

Figure 73. Manufacturing Process Analysis of Orphan Indication Treatment

Figure 74. Industry Chain Structure of Orphan Indication Treatment

Figure 75. Channels of Distribution

Figure 76. Global Orphan Indication Treatment Sales Market Forecast by Region (2024-2029)

Figure 77. Global Orphan Indication Treatment Revenue Market Share Forecast by Region (2024-2029)

Figure 78. Global Orphan Indication Treatment Sales Market Share Forecast by Type (2024-2029)

Figure 79. Global Orphan Indication Treatment Revenue Market Share Forecast by Type (2024-2029)

Figure 80. Global Orphan Indication Treatment Sales Market Share Forecast by Application (2024-2029)

Figure 81. Global Orphan Indication Treatment Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Orphan Indication Treatment Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GB242D15DBD7EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB242D15DBD7EN.html>